These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Risk-reduction and treatment of chemotherapy-induced peripheral neuropathy. Bakogeorgos M; Georgoulias V Expert Rev Anticancer Ther; 2017 Nov; 17(11):1045-1060. PubMed ID: 28868935 [TBL] [Abstract][Full Text] [Related]
23. Chemotherapy-induced peripheral neuropathy and impact on quality of life 6 months after treatment with chemotherapy. Beijers A; Mols F; Dercksen W; Driessen C; Vreugdenhil G J Community Support Oncol; 2014 Nov; 12(11):401-6. PubMed ID: 25856013 [TBL] [Abstract][Full Text] [Related]
24. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Kuriyama A; Endo K Support Care Cancer; 2018 Apr; 26(4):1051-1059. PubMed ID: 29280005 [TBL] [Abstract][Full Text] [Related]
25. Minimizing chemotherapy-induced peripheral neuropathy: preclinical and clinical development of new perspectives. Poupon L; Kerckhove N; Vein J; Lamoine S; Authier N; Busserolles J; Balayssac D Expert Opin Drug Saf; 2015 Aug; 14(8):1269-82. PubMed ID: 26058312 [TBL] [Abstract][Full Text] [Related]
26. Roles of Transient Receptor Potential Ankyrin 1 in Oxaliplatin-Induced Peripheral Neuropathy. Nakagawa T; Kaneko S Biol Pharm Bull; 2017; 40(7):947-953. PubMed ID: 28674258 [TBL] [Abstract][Full Text] [Related]
27. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis. Kanbayashi Y; Hosokawa T; Okamoto K; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Taniwaki M Anticancer Drugs; 2010 Oct; 21(9):877-81. PubMed ID: 20679888 [TBL] [Abstract][Full Text] [Related]
28. Prevention and treatment of chemotherapy-induced peripheral neuropathy. Piccolo J; Kolesar JM Am J Health Syst Pharm; 2014 Jan; 71(1):19-25. PubMed ID: 24352178 [TBL] [Abstract][Full Text] [Related]
29. Herbal medicines and chemotherapy induced peripheral neuropathy (CIPN): A critical literature review. Schloss J; Colosimo M; Vitetta L Crit Rev Food Sci Nutr; 2017 Apr; 57(6):1107-1118. PubMed ID: 25849070 [TBL] [Abstract][Full Text] [Related]
30. Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4-6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo. Myftiu B; Hundozi Z; Sermaxhaj F; Blyta A; Shala N; Jashari F; Qorraj Bytyqi H; Hyseni E; Kurtishi I Med Sci Monit; 2022 Aug; 28():e937856. PubMed ID: 36042691 [TBL] [Abstract][Full Text] [Related]
31. Pre-treatment anxiety is associated with persistent chemotherapy-induced peripheral neuropathy in women treated with neoadjuvant chemotherapy for breast cancer. Lee KM; Jung D; Hwang H; Son KL; Kim TY; Im SA; Lee KH; Hahm BJ J Psychosom Res; 2018 May; 108():14-19. PubMed ID: 29602320 [TBL] [Abstract][Full Text] [Related]
32. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. Speck RM; Sammel MD; Farrar JT; Hennessy S; Mao JJ; Stineman MG; DeMichele A J Oncol Pract; 2013 Sep; 9(5):e234-40. PubMed ID: 23943894 [TBL] [Abstract][Full Text] [Related]
34. Randomized controlled trial of neurofeedback on chemotherapy-induced peripheral neuropathy: A pilot study. Prinsloo S; Novy D; Driver L; Lyle R; Ramondetta L; Eng C; McQuade J; Lopez G; Cohen L Cancer; 2017 Jun; 123(11):1989-1997. PubMed ID: 28257146 [TBL] [Abstract][Full Text] [Related]
35. Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer. Wang XS; Shi Q; Dougherty PM; Eng C; Mendoza TR; Williams LA; Fogelman DR; Cleeland CS Oncology; 2016; 90(3):127-35. PubMed ID: 26882477 [TBL] [Abstract][Full Text] [Related]
36. The reliability and validity of a modified total neuropathy score-reduced and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in patients receiving taxanes and platinums. Smith EM; Cohen JA; Pett MA; Beck SL Cancer Nurs; 2010; 33(3):173-83. PubMed ID: 20357656 [TBL] [Abstract][Full Text] [Related]
38. Assessment of chemotherapy-induced peripheral neuropathy using the LDIFLARE technique: a novel technique to detect neural small fiber dysfunction. Sharma S; Venkitaraman R; Vas PR; Rayman G Brain Behav; 2015 Jul; 5(7):e00354. PubMed ID: 26221574 [TBL] [Abstract][Full Text] [Related]
39. Neuropathic Pain and Nerve Growth Factor in Chemotherapy-Induced Peripheral Neuropathy: Prospective Clinical-Pathological Study. Velasco R; Navarro X; Gil-Gil M; Herrando-Grabulosa M; Calls A; Bruna J J Pain Symptom Manage; 2017 Dec; 54(6):815-825. PubMed ID: 28797868 [TBL] [Abstract][Full Text] [Related]
40. Reflexology in the management of chemotherapy induced peripheral neuropathy: A pilot randomized controlled trial. Kurt S; Can G Eur J Oncol Nurs; 2018 Feb; 32():12-19. PubMed ID: 29353627 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]